 |
|||||||||||||||
 | EDUCATIONAL OVERVIEW Pulmonary arterial hypertension (PAH) is a rare disease with significant consequences, including serious functional impairment and premature death. If left untreated, PAH is rapidly fatal. Fortunately, over the past decade, the knowledge and understanding of this disease has greatly expanded. Furthermore, the availability of effective and more convenient oral and inhaled medications has allowed clinicians to better individualize therapy to meet patient treatment goals. Though there is no cure for PAH, effective treatment can significantly slow disease progression and clinical worsening. Given the serious nature of this disease and its rapid progression, optimal management approaches are essential. The Role of the Pharmacist Optimal management of patients with PAH requires early detection and diagnosis followed by a patient-centered treatment plan. By increasing their competency, pharmacists can play an important role within the multidisciplinary team when encountering patients with this disease. Given the complex and individualized nature of PAH therapy, pharmacists must have a full understanding of treatment algorithms, disease-specific therapies, and long-term monitoring recommendations based on evidence-based guidelines. As the armamentarium to treat PAH continues to expand, pharmacists must make efforts to stay informed of the latest finding in order to contribute to the optimal management of these patients. TARGET AUDIENCE |
LEARNING OBJECTIVES Upon completing this activity, participants will be able to:
EDUCATIONAL FORMAT The webcast on demand is divided into two episodes:
Note: If you received credit for attending the live symposium by the same name, you are not eligible to apply for credit for this online version. FACULTY
|
|
||||||||||||
Pharmacists
In accordance with policies set forth by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), Center for Independent Healthcare Education requires all faculty members and planning committee with an opportunity to affect the content of a continuing education activity to disclose any relevent financial relationships during the past 12 months with commercial interests. A commercial interest is any entity producing, marketing, reselling or distributing health care goods or services consumed by or used on patients. Relationships with commercial interests and conflicts of interest resulting from those relationships must be revealed to the audience and resolved prior to the activity. Planning Committee Members |
Disclosure of Financial Interest Summary
Dr. Badesch does not intend to discuss the off-label use of a product.
Cosponsorship
Commercial Support
Fee Hardware/Software Requirements Software/Hardware Connection Speed System Check Copyright Statement Privacy Policy http://www.vemcomeded.com/privacy.asp |
Center for Independent Healthcare Education is accredited by the Accreditation Council for Pharmacy Education as a provider for continuing pharmacy education. Center has assigned 1.0 contact hours (0.1 CEUs) of continuing pharmacy education credits for participating in this activity.
By clicking on an Episode,
Please take a few moments to |
 |
 |
  |
